51
|
Jackson RA, Chen ES. Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs. Pharmacol Ther 2016; 162:69-85. [DOI: 10.1016/j.pharmthera.2016.01.014] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
52
|
Caropreso V, Darvishi E, Turbyville TJ, Ratnayake R, Grohar PJ, McMahon JB, Woldemichael GM. Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells. J Biol Chem 2016; 291:10058-66. [PMID: 26961871 PMCID: PMC4858959 DOI: 10.1074/jbc.m115.701375] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 03/03/2016] [Indexed: 12/22/2022] Open
Abstract
High-throughput screening of extracts from plants, marine, and micro-organisms led to the identification of the extract from the plant Phyllanthus engleri as the most potent inhibitor of EWS-FLI1 induced luciferase reporter expression. Testing of compounds isolated from this extract in turn led to the identification of Englerin A (EA) as the active constituent of the extract. EA induced both necrosis and apoptosis in Ewing cells subsequent to a G2M accumulation of cells in the cell cycle. It also impacted clonogenic survival and anchorage-independent proliferation while also decreasing the proportion of chemotherapy-resistant cells identified by high ALDH activity. EA also caused a sustained increase in cytosolic calcium levels. EA appears to exert its effect on Ewing cells through a decrease in phosphorylation of EWS-FLI1 and its ability to bind DNA. This effect is mediated, at least in part, through a decrease in the levels of the calcium-dependent protein kinase PKC-βI after a transient up-regulation.
Collapse
MESH Headings
- Aldehyde Dehydrogenase/genetics
- Aldehyde Dehydrogenase/metabolism
- Apoptosis/drug effects
- Apoptosis/genetics
- Bone Neoplasms/drug therapy
- Bone Neoplasms/genetics
- Bone Neoplasms/metabolism
- Bone Neoplasms/pathology
- Cell Line, Tumor
- DNA, Neoplasm/genetics
- DNA, Neoplasm/metabolism
- Humans
- Oncogene Proteins, Fusion/genetics
- Oncogene Proteins, Fusion/metabolism
- Phosphorylation/drug effects
- Phosphorylation/genetics
- Protein Binding/drug effects
- Proto-Oncogene Protein c-fli-1/genetics
- Proto-Oncogene Protein c-fli-1/metabolism
- RNA-Binding Protein EWS/genetics
- RNA-Binding Protein EWS/metabolism
- Sarcoma, Ewing/drug therapy
- Sarcoma, Ewing/genetics
- Sarcoma, Ewing/metabolism
- Sarcoma, Ewing/pathology
- Sesquiterpenes, Guaiane/pharmacology
Collapse
Affiliation(s)
- Vittorio Caropreso
- From the Molecular Targets Laboratory, NCI, National Institutes of Health
| | - Emad Darvishi
- From the Molecular Targets Laboratory, NCI, National Institutes of Health
| | - Thomas J Turbyville
- Optical Microscopy and Analysis Laboratory, Leidos Biomedical Research, Inc., and
| | - Ranjala Ratnayake
- From the Molecular Targets Laboratory, NCI, National Institutes of Health
| | - Patrick J Grohar
- Center for Cancer and Cell Biology, Van Andel Institute, Grand Rapids, Michigan 49503, and Division of Hematology/Oncology, Helen DeVos Children's Hospital, Grand Rapids, Michigan 49503
| | - James B McMahon
- From the Molecular Targets Laboratory, NCI, National Institutes of Health
| | - Girma M Woldemichael
- Basic Science Program, Leidos Biomedical Research, Inc., Molecular Targets Laboratory, Frederick National Laboratory, Frederick, Maryland 21702,
| |
Collapse
|
53
|
López-Suárez L, Riesgo L, Bravo F, Ransom TT, Beutler JA, Echavarren AM. Synthesis and Biological Evaluation of New (-)-Englerin Analogues. ChemMedChem 2016; 11:1003-7. [PMID: 27005578 PMCID: PMC4926265 DOI: 10.1002/cmdc.201600040] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2016] [Revised: 03/04/2016] [Indexed: 11/07/2022]
Abstract
We report the synthesis and biological evaluation of a series of (-)-englerin A analogues obtained along our previously reported synthetic route based on a stereoselective gold(I) cycloaddition process. This synthetic route is a convenient platform to access analogues with broad structural diversity and has led us to the discovery of unprecedented and easier-to-synthesize derivatives with an unsaturation in the cyclopentyl ring between C4 and C5. We also introduce novel analogues in which the original isopropyl motif has been substituted with cyclohexyl, phenyl, and cyclopropyl moieties. The high selectivity and growth-inhibitory activity shown by these new derivatives in renal cancer cell lines opens new ways toward the final goal of finding effective drugs for the treatment of renal cell carcinoma (RCC).
Collapse
Affiliation(s)
- Laura López-Suárez
- Institute of Chemical Research of Catalonia (ICIQ), Av. Països Catalans 16, 43007, Tarragona, Spain
| | - Lorena Riesgo
- Institute of Chemical Research of Catalonia (ICIQ), Av. Països Catalans 16, 43007, Tarragona, Spain.,Institute of Polymer Science and Technology, ICTP-CSIC, Juan de la Cierva 3, 28006, Madrid, Spain
| | - Fernando Bravo
- Institute of Chemical Research of Catalonia (ICIQ), Av. Països Catalans 16, 43007, Tarragona, Spain
| | - Tanya T Ransom
- Molecular Targets Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA
| | - John A Beutler
- Molecular Targets Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA.
| | - Antonio M Echavarren
- Institute of Chemical Research of Catalonia (ICIQ), Av. Països Catalans 16, 43007, Tarragona, Spain. .,Departament de Química Analítica i Química Orgánica, Universitat Rovira i Virgili, C/Marcel⋅li Domingo s/n, 43007, Tarragona, Spain.
| |
Collapse
|
54
|
Metabolic alterations in renal cell carcinoma. Cancer Treat Rev 2015; 41:767-76. [DOI: 10.1016/j.ctrv.2015.07.002] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2015] [Revised: 06/30/2015] [Accepted: 07/02/2015] [Indexed: 02/06/2023]
|
55
|
Hanari T, Shimada N, Kurosaki Y, Thrimurtulu N, Nambu H, Anada M, Hashimoto S. Asymmetric Total Synthesis of (−)-Englerin A through Catalytic Diastereo- and Enantioselective Carbonyl Ylide Cycloaddition. Chemistry 2015; 21:11671-6. [DOI: 10.1002/chem.201502009] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Indexed: 12/20/2022]
|
56
|
Abstract
Protein kinase Cθ (PKCθ) is a key enzyme in T-lymphocytes where it plays an important role in signal transduction downstream of the activated T-cell receptor (TCR) and the CD28 co-stimulatory receptor. Antigenic stimulation of T-cells triggers PKCθ translocation to the centre of the immunological synapse (IS) at the contact site between antigen-specific T-cells and antigen-presenting cells (APCs). The IS-residing PKCθ phosphorylates and activates effector molecules that transduce signals into distinct subcellular compartments and activate the transcription factors, nuclear factor κB (NF-κB), nuclear factor of activated T-cells (NFAT) and activating protein 1 (AP-1), which are essential for the induction of T-cell-mediated responses. Besides its major biological role in T-cells, PKCθ is expressed in several additional cell types and is involved in a variety of distinct physiological and pathological phenomena. For example, PKCθ is expressed at high levels in platelets where it regulates signal transduction from distinct surface receptors, and is required for optimal platelet activation and aggregation, as well as haemostasis. In addition, PKCθ is involved in physiological processes regulating insulin resistance and susceptibility to obesity, and is expressed at high levels in gastrointestinal stromal tumours (GISTs), although the functional importance of PKCθ in these processes and cell types is not fully clear. The present article briefly reviews selected topics relevant to the biological roles of PKCθ in health and disease.
Collapse
|
57
|
Reddy BVS, Someswarao B, Prudhviraju N, Reddy BJM, Sridhar B, Kumar SK. An iodine catalyzed metal free domino process for the stereoselective synthesis of oxygen bridged bicyclic ethers. Org Biomol Chem 2015; 13:6737-41. [PMID: 25994362 DOI: 10.1039/c5ob00518c] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A domino reaction has been developed for the synthesis of oxygen bridged bicyclic ethers through the coupling of 4-(2-hydroxyethyl)cyclohex-3-enols with aldehydes in the presence of 10 mol% of molecular iodine in dichloromethane at 25 °C. This method is highly diastereoselective affording the corresponding bicyclic ethers, i.e. octahydro-4a,7-epoxyisochromenes in good yields with high selectivity. It is the first report on the synthesis of oxygen bridged bicyclic ethers using a domino Prins strategy.
Collapse
Affiliation(s)
- B V Subba Reddy
- Natural Product Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, 500 007, Hyderabad, India.
| | | | | | | | | | | |
Collapse
|
58
|
Carson C, Raman P, Tullai J, Xu L, Henault M, Thomas E, Yeola S, Lao J, McPate M, Verkuyl JM, Marsh G, Sarber J, Amaral A, Bailey S, Lubicka D, Pham H, Miranda N, Ding J, Tang HM, Ju H, Tranter P, Ji N, Krastel P, Jain RK, Schumacher AM, Loureiro JJ, George E, Berellini G, Ross NT, Bushell SM, Erdemli G, Solomon JM. Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation. PLoS One 2015; 10:e0127498. [PMID: 26098886 PMCID: PMC4476799 DOI: 10.1371/journal.pone.0127498] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Accepted: 04/14/2015] [Indexed: 01/19/2023] Open
Abstract
Englerin A is a structurally unique natural product reported to selectively inhibit growth of renal cell carcinoma cell lines. A large scale phenotypic cell profiling experiment (CLiP) of englerin A on ¬over 500 well characterized cancer cell lines showed that englerin A inhibits growth of a subset of tumor cell lines from many lineages, not just renal cell carcinomas. Expression of the TRPC4 cation channel was the cell line feature that best correlated with sensitivity to englerin A, suggesting the hypothesis that TRPC4 is the efficacy target for englerin A. Genetic experiments demonstrate that TRPC4 expression is both necessary and sufficient for englerin A induced growth inhibition. Englerin A induces calcium influx and membrane depolarization in cells expressing high levels of TRPC4 or its close ortholog TRPC5. Electrophysiology experiments confirmed that englerin A is a TRPC4 agonist. Both the englerin A induced current and the englerin A induced growth inhibition can be blocked by the TRPC4/C5 inhibitor ML204. These experiments confirm that activation of TRPC4/C5 channels inhibits tumor cell line proliferation and confirms the TRPC4 target hypothesis generated by the cell line profiling. In selectivity assays englerin A weakly inhibits TRPA1, TRPV3/V4, and TRPM8 which suggests that englerin A may bind a common feature of TRP ion channels. In vivo experiments show that englerin A is lethal in rodents near doses needed to activate the TRPC4 channel. This toxicity suggests that englerin A itself is probably unsuitable for further drug development. However, since englerin A can be synthesized in the laboratory, it may be a useful chemical starting point to identify novel modulators of other TRP family channels.
Collapse
Affiliation(s)
- Cheryl Carson
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Pichai Raman
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Jennifer Tullai
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Lei Xu
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Martin Henault
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Emily Thomas
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Sarita Yeola
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Jianmin Lao
- Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America
| | - Mark McPate
- Novartis Institutes for Biomedical Research, Horsham, United Kingdom
| | - J. Martin Verkuyl
- Novartis Institutes for Biomedical Research, Horsham, United Kingdom
| | - George Marsh
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Jason Sarber
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Adam Amaral
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Scott Bailey
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Danuta Lubicka
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Helen Pham
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Nicolette Miranda
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Jian Ding
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Hai-Ming Tang
- Novartis Institutes for Biomedical Research, East Hanover, New Jersey, United States of America
| | - Haisong Ju
- Novartis Institutes for Biomedical Research, East Hanover, New Jersey, United States of America
| | - Pamela Tranter
- Novartis Institutes for Biomedical Research, Horsham, United Kingdom
| | - Nan Ji
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Philipp Krastel
- Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Rishi K. Jain
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Andrew M. Schumacher
- Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America
| | - Joseph J. Loureiro
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Elizabeth George
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Giuliano Berellini
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Nathan T. Ross
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Simon M. Bushell
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Gül Erdemli
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
| | - Jonathan M. Solomon
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|
59
|
Design and synthesis of terpene based englerin A mimics using chromium oxide mediated remote CH 2 oxidation. Tetrahedron Lett 2015. [DOI: 10.1016/j.tetlet.2015.02.071] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
60
|
Shah SP, Lonial S, Boise LH. When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. Mol Cancer Res 2015; 13:1163-73. [PMID: 26013169 DOI: 10.1158/1541-7786.mcr-15-0135] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Accepted: 05/13/2015] [Indexed: 01/01/2023]
Abstract
Multiple myeloma is a plasma cell malignancy with an estimated 26,850 new cases and 11,240 deaths in 2015 in the United States. Two main classes of agents are the mainstays of therapy-proteasome inhibitors (PI) and immunomodulatory drugs (IMiD). Other new targets are emerging rapidly, including monoclonal antibodies and histone deacetylase (HDAC) inhibitors. These therapeutic options have greatly improved overall survival, but currently only 15% to 20% of patients experience long-term progression-free survival or are cured. Therefore, improvement in treatment options is needed. One potential means of improving clinical options is to target resistance mechanisms for current agents. For example, eliminating the cytoprotective heat-shock response that protects myeloma cells from proteasome inhibition may enhance PI-based therapies. The transcription factor heat-shock factor 1 (HSF1) is the master regulator of the heat-shock response. HSF1 is vital in the proteotoxic stress response, and its activation is controlled by posttranslational modifications (PTM). This review details the mechanisms of HSF1 regulation and discusses leveraging that regulation to enhance PI activity.
Collapse
Affiliation(s)
- Shardule P Shah
- Department of Hematology and Medical Oncology, Winship, Cancer Institute of Emory University and the Emory University School of Medicine, Atlanta, Georgia
| | - Sagar Lonial
- Department of Hematology and Medical Oncology, Winship, Cancer Institute of Emory University and the Emory University School of Medicine, Atlanta, Georgia
| | - Lawrence H Boise
- Department of Hematology and Medical Oncology, Winship, Cancer Institute of Emory University and the Emory University School of Medicine, Atlanta, Georgia. Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia.
| |
Collapse
|
61
|
Akbulut Y, Gaunt HJ, Muraki K, Ludlow MJ, Amer MS, Bruns A, Vasudev NS, Radtke L, Willot M, Hahn S, Seitz T, Ziegler S, Christmann M, Beech DJ, Waldmann H. (-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl 2015; 54:3787-91. [PMID: 25707820 PMCID: PMC7116557 DOI: 10.1002/anie.201411511] [Citation(s) in RCA: 150] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2014] [Indexed: 12/21/2022]
Abstract
Current therapies for common types of cancer such as renal cell cancer are often ineffective and unspecific, and novel pharmacological targets and approaches are in high demand. Here we show the unexpected possibility for the rapid and selective killing of renal cancer cells through activation of calcium-permeable nonselective transient receptor potential canonical (TRPC) calcium channels by the sesquiterpene (-)-englerin A. This compound was found to be a highly efficient, fast-acting, potent, selective, and direct stimulator of TRPC4 and TRPC5 channels. TRPC4/5 activation through a high-affinity extracellular (-)-englerin A binding site may open up novel opportunities for drug discovery aimed at renal cancer.
Collapse
Affiliation(s)
- Yasemin Akbulut
- Max-Planck-Institut für Molekulare Physiologie, Otto-Hahn-Straße 11, 44227 Dortmund, Germany, Tel. +49 (0) 231-133-2400
- Technische Universität Dortmund, Fakultät Chemie, Lehrbereich Chemische Biologie, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
| | - Hannah J Gaunt
- School of Medicine, Garstang Building, Mount Preston Street, University of Leeds, Leeds, LS2 9JT, England, UK; Tel +44 (0) 113 34 34323
| | - Katsuhiko Muraki
- School of Pharmacy, Aichi-Gakuin University, 1-100 Kusumoto, Chikusa, Nagoya 464-8650, Japan
| | - Melanie J Ludlow
- School of Medicine, Garstang Building, Mount Preston Street, University of Leeds, Leeds, LS2 9JT, England, UK; Tel +44 (0) 113 34 34323
| | - Mohamed S Amer
- School of Medicine, Garstang Building, Mount Preston Street, University of Leeds, Leeds, LS2 9JT, England, UK; Tel +44 (0) 113 34 34323
- Clinical Physiology Department, Faculty of Medicine, Menoufiya University, Egypt
| | - Alexander Bruns
- School of Medicine, Garstang Building, Mount Preston Street, University of Leeds, Leeds, LS2 9JT, England, UK; Tel +44 (0) 113 34 34323
| | - Naveen S Vasudev
- School of Medicine, Garstang Building, Mount Preston Street, University of Leeds, Leeds, LS2 9JT, England, UK; Tel +44 (0) 113 34 34323
| | - Lea Radtke
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany, Tel +49 (0) 30 83860182
| | - Matthieu Willot
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany, Tel +49 (0) 30 83860182
| | - Sven Hahn
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany, Tel +49 (0) 30 83860182
| | - Tobias Seitz
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany, Tel +49 (0) 30 83860182
| | - Slava Ziegler
- Max-Planck-Institut für Molekulare Physiologie, Otto-Hahn-Straße 11, 44227 Dortmund, Germany, Tel. +49 (0) 231-133-2400
| | - Mathias Christmann
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany, Tel +49 (0) 30 83860182
| | - David J Beech
- School of Medicine, Garstang Building, Mount Preston Street, University of Leeds, Leeds, LS2 9JT, England, UK; Tel +44 (0) 113 34 34323
| | - Herbert Waldmann
- Max-Planck-Institut für Molekulare Physiologie, Otto-Hahn-Straße 11, 44227 Dortmund, Germany, Tel. +49 (0) 231-133-2400
- Technische Universität Dortmund, Fakultät Chemie, Lehrbereich Chemische Biologie, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
| |
Collapse
|
62
|
Home T, Jensen RA, Rao R. Heat shock factor 1 in protein homeostasis and oncogenic signal integration. Cancer Res 2015; 75:907-12. [PMID: 25724679 DOI: 10.1158/0008-5472.can-14-2905] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Heat shock factor 1 (HSF1) is a stress-inducible transcription factor and has been described as a multi-faceted modulator of tumorigenesis. Heat shock, accumulation of misfolded proteins, or malignant transformation promotes the activation and nuclear translocation of HSF1, where it binds to the promoters of heat shock proteins and an array of nonheat shock-regulated proteins to upregulate their transcription. These stress-responsive and tumor-promoting genes in turn alter the ability of tumor cells to respond to a variety of stresses and enable them to thrive in less than favorable growth conditions. Although a direct role for HSF1 in promoting mRNA transcription of tumor-promoting genes has been suggested, it appears that this property is context- and cell-type dependent. Furthermore, recent studies have demonstrated a direct involvement of mTOR signaling in regulating HSF1-mediated transcription, thus establishing a direct link between protein translation and HSF1 activity. Interestingly, there is a growing understanding of the signaling pathways that are modulated by HSF1 in a variety of tumor types and the co-option of these survival pathways by HSF1 to promote tumorigenesis. This review will focus on the role of HSF1 in protein homeostasis and HSF1-mediated oncogenic signaling pathways that together promote tumorigenesis.
Collapse
Affiliation(s)
- Trisha Home
- The University of Kansas Cancer Center, Kansas City, Kansas
| | - Roy A Jensen
- The University of Kansas Cancer Center, Kansas City, Kansas
| | - Rekha Rao
- The University of Kansas Cancer Center, Kansas City, Kansas.
| |
Collapse
|
63
|
Akbulut Y, Gaunt HJ, Muraki K, Ludlow MJ, Amer MS, Bruns A, Vasudev NS, Radtke L, Willot M, Hahn S, Seitz T, Ziegler S, Christmann M, Beech DJ, Waldmann H. (−)-Englerin A is a Potent and Selective Activator of TRPC4 and TRPC5 Calcium Channels. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201411511] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
64
|
Anticancer activity of Aristolochia ringens Vahl. (Aristolochiaceae). J Tradit Complement Med 2014; 5:35-41. [PMID: 26151007 PMCID: PMC4488040 DOI: 10.1016/j.jtcme.2014.05.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2013] [Revised: 05/21/2014] [Accepted: 05/22/2014] [Indexed: 01/19/2023] Open
Abstract
Cancer is a leading cause of death worldwide and sustained focus is on the discovery and development of newer and better tolerated anticancer drugs especially from plants. The sulforhodamine B (SRB) in vitro cytotoxicity assay, sarcoma-180 (S-180) ascites and solid tumor, and L1210 lymphoid leukemia in vivo models were used to investigate the anticancer activity of root extracts of Aristolochia ringens Vahl. (Aristolochiaceae; 馬兜鈴 mǎ dōu líng). AR-A001 (IC50 values of 20 μg/mL, 22 μg/mL, 3 μg/mL, and 24 μg/mL for A549, HCT-116, PC3, and THP-1 cell lines, respectively), and AR-A004 (IC50 values of 26 μg/mL, 19.5 μg/mL, 12 μg/mL, 28 μg/mL, 30 μg/mL, and 22 μg/mL for A549, HCT-116, PC3, A431, HeLa, and THP-1, respectively), were observed to be significantly active in vitro. Potency was highest with AR-A001 and AR-A004 for PC3 with IC50 values of 3 μg/mL and 12 μg/mL, respectively. AR-A001 and AR-A004 produced significant (p < 0.05–0.001) dose-dependent inhibition of tumor growth in the S-180 ascites model with peak effects produced at the highest dose of 120 mg/kg. Inhibition values were 79.51% and 89.98% for AR-A001 and AR-A004, respectively. In the S-180 solid tumor model, the inhibition of tumor growth was 29.45% and 50.50% for AR-A001 (120 mg/kg) and AR-A004 (110 mg/kg), respectively, compared to 50.18% for 5-fluorouracil (5-FU; 20 mg/kg). AR-A001 and AR-A004 were also significantly active in the leukemia model with 211.11% and 155.56% increase in mean survival time (MST) compared to a value of 211.11% for 5-FU. In conclusion, the ethanolic (AR-A001) and dichloromethane:methanol (AR-A004) root extracts of AR possess significant anticancer activities in vitro and in vivo.
Collapse
|
65
|
Sourbier C, Ricketts CJ, Matsumoto S, Crooks DR, Liao PJ, Mannes PZ, Yang Y, Wei MH, Srivastava G, Ghosh S, Chen V, Vocke CD, Merino M, Srinivasan R, Krishna MC, Mitchell JB, Pendergast AM, Rouault TA, Neckers L, Linehan WM. Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. Cancer Cell 2014; 26:840-850. [PMID: 25490448 PMCID: PMC4386283 DOI: 10.1016/j.ccell.2014.10.005] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Revised: 06/06/2014] [Accepted: 10/07/2014] [Indexed: 01/01/2023]
Abstract
Patients with germline fumarate hydratase (FH) mutation are predisposed to develop aggressive kidney cancer with few treatment options and poor therapeutic outcomes. Activity of the proto-oncogene ABL1 is upregulated in FH-deficient kidney tumors and drives a metabolic and survival signaling network necessary to cope with impaired mitochondrial function and abnormal accumulation of intracellular fumarate. Excess fumarate indirectly stimulates ABL1 activity, while restoration of wild-type FH abrogates both ABL1 activation and the cytotoxicity caused by ABL1 inhibition or knockdown. ABL1 upregulates aerobic glycolysis via the mTOR/HIF1α pathway and neutralizes fumarate-induced proteotoxic stress by promoting nuclear localization of the antioxidant response transcription factor NRF2. Our findings identify ABL1 as a pharmacologically tractable therapeutic target in glycolytically dependent, oxidatively stressed tumors.
Collapse
Affiliation(s)
- Carole Sourbier
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Christopher J Ricketts
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Shingo Matsumoto
- Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Daniel R Crooks
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Pei-Jyun Liao
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Philip Z Mannes
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Youfeng Yang
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Ming-Hui Wei
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Gaurav Srivastava
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Sanchari Ghosh
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Viola Chen
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Cathy D Vocke
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Maria Merino
- Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
| | - Ramaprasad Srinivasan
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Murali C Krishna
- Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - James B Mitchell
- Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Ann Marie Pendergast
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA
| | - Tracey A Rouault
- Molecular Medicine Program, Eunice Kennedy Shriver National Institute of Child Health and Development, Bethesda, MD 20892, USA
| | - Len Neckers
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - W Marston Linehan
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
| |
Collapse
|
66
|
Sunassee S, Ransom T, Henrich C, Beutler JA, Covell DG, McMahon JB, Gustafson KR. Steroidal alkaloids from the marine sponge Corticium niger that inhibit growth of human colon carcinoma cells. JOURNAL OF NATURAL PRODUCTS 2014; 77:2475-80. [PMID: 25338277 PMCID: PMC4251534 DOI: 10.1021/np500556t] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Indexed: 05/25/2023]
Abstract
Bioinformatic analysis of data from the NCI-60 cell cytotoxicity screen revealed a subset of extracts that showed selective cytotoxic activity toward human colon carcinoma cell lines. Bioassay-guided fractionation of a colon cancer selective extract from a Philippines collection of the marine sponge Corticium niger provided two new steroidal alkaloids, plakinamines N (1) and O (2), along with two known compounds of the plakinamine class (3, 4). The structures of these compounds were elucidated by interpretation of combined MS and NMR spectroscopic data. Plakinamines N (1), O (2), and J (4) were tested for antiproliferative activity in the NCI-60 screen, and they showed enhanced inhibitory effects against all of the colon cell lines with mean GI50 values of 11.5, 2.4, and 1.4 μM, respectively.
Collapse
Affiliation(s)
- Suthananda
N. Sunassee
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Tanya Ransom
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Curtis
J. Henrich
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic
Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - John A. Beutler
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - David G. Covell
- Screening
Technologies Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - James B. McMahon
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R. Gustafson
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
67
|
Akindele AJ, Mahajan G, Wani ZA, Sharma S, Satti NK, Adeyemi OO, Mondhe DM, Saxena AK. Anticancer activity of the phytomedicine DAS-77. Integr Cancer Ther 2014; 14:57-64. [PMID: 25351406 DOI: 10.1177/1534735414555807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
This study was designed to investigate the anticancer activity of extracts of the phytomedicine DAS-77. The sulforhodamine B (SRB) in vitro cytotoxicity assay, Sarcoma-180 (S-180) ascites and solid tumor, and L1210 lymphoid leukemia in vivo models were employed. DAS-A001 (ethanol extract, IC50 12 and 13 µg/mL with HCT-116 and PC3, respectively); DAS-A002 (hydroethanol extract, IC50 <5 and 13 µg/mL with HCT-116 and PC3, respectively); DAS-A003 (aqueous extract, IC50 <5 µg/mL with THP-1); and DAS-A004 (dichloromethane:methanol extract; IC50 <5 and 17 µg/mL with HCT-116 and PC3, respectively) demonstrated significant activity in vitro. DAS-A002 and DAS-A003 (80-120 mg/kg) elicited significant (P < .05-.001) dose-dependent inhibition of tumor growth in the S-180 ascites model. Peak effects were produced at the highest dose of 120 mg/kg with inhibition values of 87.50% and 89.23% for DAS-A002 and DAS-A003, respectively, compared with a value of 97.27% for 5-FU (20 mg/kg). As regards the S-180 solid tumor model, inhibition of tumor growth was found to be 52.56% and 37.95%, respectively, for DAS-A002 and DAS-A003. The effect of DAS-A002 was comparable and not significantly different (P > .05) from that of 5-FU (20 mg/kg; 50.18% inhibition). DAS-A003 but not DAS-A002 showed significant activity in the leukemia model with 177.78% increase in mean survival time relative to 211.11% for 5-FU. Findings in this study suggest that the hydroethanol and aqueous extracts of DAS-77 possess significant anticancer activity.
Collapse
Affiliation(s)
- Abidemi J Akindele
- Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India Natural Products Chemistry Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India Department of Pharmacology, Therapeutics & Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria
| | - Girish Mahajan
- Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India
| | - Zahoor A Wani
- Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India
| | - Sadhana Sharma
- Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India
| | - Naresh K Satti
- Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India
| | - Olufunmilayo O Adeyemi
- Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India
| | - Dilip M Mondhe
- Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India
| | - Ajit K Saxena
- Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Council of Scientific & Industrial Research, Jammu-Tawi, Jammu & Kashmir, India
| |
Collapse
|
68
|
Jansen DJ, Shenvi RA. Synthesis of medicinally relevant terpenes: reducing the cost and time of drug discovery. Future Med Chem 2014; 6:1127-48. [PMID: 25078134 PMCID: PMC4162426 DOI: 10.4155/fmc.14.71] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Terpenoids constitute a significant fraction of molecules produced by living organisms that have found use in medicine and other industries. Problems associated with their procurement and adaptation for human use can be solved using chemical synthesis, which is an increasingly economical option in the modern era of chemistry. This article documents, by way of individual case studies, strategies for reducing the time and cost of terpene synthesis for drug discovery. A major trend evident in recent syntheses is that complex terpenes are increasingly realistic starting points for both medicinal chemistry campaigns and large-scale syntheses, at least in the context of the academic laboratory, and this trend will likely penetrate the commercial sector in the near future.
Collapse
Affiliation(s)
- Daniel J Jansen
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Ryan A Shenvi
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| |
Collapse
|
69
|
Zhang Y, Luo T, Yang Z. Strategic innovation in the total synthesis of complex natural products using gold catalysis. Nat Prod Rep 2014; 31:489-503. [DOI: 10.1039/c3np70075e] [Citation(s) in RCA: 119] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
This review has been organized from the perspective of synthetic target families, with emphasis on the use of gold-catalyzed transformations and cascade reactions that significantly increase molecular complexity.
Collapse
Affiliation(s)
- Yun Zhang
- Laboratory of Chemical Genomics
- School of Chemical Biology and Biotechnology
- Peking University Shenzhen Graduate School
- Shenzhen 518055, China
| | - Tuoping Luo
- Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, and Beijing National Laboratory for Molecular Science (BNLMS)
- Peking-Tsinghua Center for Life Sciences
- Peking University
- Beijing 100871, China
| | - Zhen Yang
- Laboratory of Chemical Genomics
- School of Chemical Biology and Biotechnology
- Peking University Shenzhen Graduate School
- Shenzhen 518055, China
- Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, and Beijing National Laboratory for Molecular Science (BNLMS)
| |
Collapse
|
70
|
Williams RT, Yu AL, Diccianni MB, Theodorakis EA, Batova A. Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2013; 32:57. [PMID: 23958461 PMCID: PMC3765946 DOI: 10.1186/1756-9966-32-57] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/27/2013] [Accepted: 08/08/2013] [Indexed: 12/28/2022]
Abstract
Renal cell carcinoma (RCC), the most common malignancy of the kidney, is refractory to standard therapy and has an incidence that continues to rise. Screening of plant extracts in search of new agents to treat RCC resulted in the discovery of englerin A (EA), a natural product exhibiting potent selective cytotoxicity against renal cancer cells. Despite the establishment of synthetic routes to the synthesis of EA, very little is known about its mechanism of action. The results of the current study demonstrate for the first time that EA induces apoptosis in A498 renal cancer cells in addition to necrosis. The induction of apoptosis by EA required at least 24 h and was caspase independent. In addition, EA induced increased levels of autophagic vesicles in A498 cells which could be inhibited by nonessential amino acids (NEAA), known inhibitors of autophagy. Interestingly, inhibition of autophagy by NEAA did not diminish cell death suggesting that autophagy is not a cell death mechanism and likely represents a cell survival mechanism which ultimately fails. Apart from cell death, our results demonstrated that cells treated with EA accumulated in the G2 phase of the cell cycle indicating a block in G2/M transition. Moreover, our results determined that EA inhibited the activation of both AKT and ERK, kinases which are activated in cancer and implicated in unrestricted cell proliferation and induction of autophagy. The phosphorylation status of the cellular energy sensor, AMPK, appeared unaffected by EA. The high renal cancer selectivity of EA combined with its ability to induce multiple mechanisms of cell death while inhibiting pathways driving cell proliferation, suggest that EA is a highly unique agent with great potential as a therapeutic lead for the treatment of RCC.
Collapse
Affiliation(s)
- Richard T Williams
- Department of Chemistry and Biochemistry, University of California, 9500 Gilman Drive, La Jolla, CA 92093, USA.
| | | | | | | | | |
Collapse
|
71
|
Linehan WM, Rouault TA. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. Clin Cancer Res 2013; 19:3345-52. [PMID: 23633457 DOI: 10.1158/1078-0432.ccr-13-0304] [Citation(s) in RCA: 150] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a hereditary cancer syndrome in which affected individuals are at risk for development of cutaneous and uterine leiomyomas and an aggressive form of type II papillary kidney cancer. HLRCC is characterized by germline mutation of the tricarboxylic acid (TCA) cycle enzyme, fumarate hydratase (FH). FH-deficient kidney cancer is characterized by impaired oxidative phosphorylation and a metabolic shift to aerobic glycolysis, a form of metabolic reprogramming referred to as the Warburg effect. Increased glycolysis generates ATP needed for increased cell proliferation. In FH-deficient kidney cancer, levels of AMP-activated protein kinase (AMPK), a cellular energy sensor, are decreased resulting in diminished p53 levels, decreased expression of the iron importer, DMT1, leading to low cellular iron levels, and to enhanced fatty acid synthesis by diminishing phosphorylation of acetyl CoA carboxylase, a rate-limiting step for fatty acid synthesis. Increased fumarate and decreased iron levels in FH-deficient kidney cancer cells inactivate prolyl hydroxylases, leading to stabilization of hypoxia-inducible factor (HIF)-1α and increased expression of genes such as VEGF and glucose transporter 1 (GLUT1) to provide fuel needed for rapid growth demands. Several therapeutic approaches for targeting the metabolic basis of FH-deficient kidney cancer are under development or are being evaluated in clinical trials, including the use of agents such as metformin, which would reverse the inactivation of AMPK, approaches to inhibit glucose transport, lactate dehydrogenase A (LDHA), the antioxidant response pathway, the heme oxygenase pathway, and approaches to target the tumor vasculature and glucose transport with agents such as bevacizumab and erlotinib. These same types of metabolic shifts, to aerobic glycolysis with decreased oxidative phosphorylation, have been found in a wide variety of other cancer types. Targeting the metabolic basis of a rare cancer such as FH-deficient kidney cancer will hopefully provide insights into the development of effective forms of therapies for other, more common forms of cancer.
Collapse
Affiliation(s)
- W Marston Linehan
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
| | | |
Collapse
|
72
|
Zahel M, Keßberg A, Metz P. Eine kurze enantioselektive Totalsynthese von (−)-Englerin A. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201301247] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
73
|
Zahel M, Keßberg A, Metz P. A Short Enantioselective Total Synthesis of (−)-Englerin A. Angew Chem Int Ed Engl 2013; 52:5390-2. [DOI: 10.1002/anie.201301247] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Indexed: 11/08/2022]
|